Volagidemab

Volagidemab
Monoclonal antibody
Type?
Clinical data
Other namesREMD-477; AMG-477
ATC code
  • None
Identifiers
CAS Number
DrugBank
UNII

Volagidemab (development name REMD-477) is a monoclonal antibody that targets the glucagon receptor. It is developed by REMD Biotherapeutics for type 1 and type 2 diabetes. A phase II trial did not meet its primary endpoint.[1][2][3]

Research

A systematic review and meta-analysis of volagidemab, published in 2024, found it to be potentially beneficial in the treatment of type 1 diabetes.[4]

References

  1. ^ Pettus J, Reeds D, Cavaiola TS, Boeder S, Levin M, Tobin G, et al. (May 2018). "Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial". Diabetes, Obesity and Metabolism. 20 (5): 1302–1305. doi:10.1111/dom.13202. PMC 6181222. PMID 29283470.
  2. ^ Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, et al. (1 June 2021). "236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial". Diabetes. 70 (Supplement 1). doi:10.2337/db21-236-OR. S2CID 237783919.
  3. ^ Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, et al. (October 2022). "Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial". Nature Medicine. 28 (10): 2092–2099. doi:10.1038/s41591-022-02011-x. PMC 9872851. PMID 36192552.
  4. ^ Dutta D, Kamrul-Hasan AB, Surana V, Singla R, Khandelwal D, Aggarwal S, et al. (December 2024). "Efficacy and safety of the glucagon receptor antagonist volagidemab in type-1 diabetes: A systematic review and meta-analysis". Annals of the New York Academy of Sciences. 1543 (1): 94–101. doi:10.1111/nyas.15262. PMID 39625039.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.